Compass Therapeutics, Inc. (CMPX) Income Statement
CMPX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCMPX revenue and net income
CMPX profit margins
CMPX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −100.0% | — | — | — |
| Gross profit | −273.2% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CMPX quarterly EPS vs estimates
Compass Therapeutics beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 4, 2026 (estimate $-0.12).
CMPX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $850,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.5M | $0 | $1.9M | $1.9M | $1.6M | $2.4M | $2.1M | $1.9M |
| Gross profit | −$1.5M | $850,000 | −$1.9M | −$1.9M | −$1.6M | −$2.4M | −$2.1M | −$1.9M |
| Research & development | $56.0M | $42.3M | $38.1M | $30.0M | $20.3M | $14.9M | $22.4M | $27.1M |
| Sales, general & admin | $16.9M | $15.1M | $12.2M | $11.7M | $10.9M | $12.9M | $11.6M | $11.2M |
| Total operating expenses | $71.4M | $57.5M | $50.4M | $41.7M | $81.9M | $27.8M | $34.1M | $38.3M |
| Operating income | −$72.8M | −$56.6M | −$50.4M | −$41.7M | −$81.9M | −$27.8M | −$34.1M | −$38.3M |
| Interest income | $6.4M | $7.3M | $7.9M | $2.4M | $29,000 | $88,000 | $743,000 | $663,000 |
| Interest expense | — | — | — | $2.4M | $370,000 | $908,000 | $1.2M | $767,000 |
| Income before taxes | −$66.5M | −$49.4M | −$42.5M | −$39.2M | −$82.2M | −$29.5M | −$34.7M | −$38.2M |
| Income taxes | — | — | — | −$2.4M | $370,000 | $32,000 | $91,000 | $103,000 |
| Net income | −$66.5M | −$49.4M | −$42.5M | −$39.2M | −$82.2M | −$29.5M | −$34.7M | −$38.3M |
| EBITDA | −$65.0M | −$47.6M | −$40.6M | −$35.0M | −$80.2M | −$25.4M | −$31.9M | −$35.7M |
| EPS (diluted) | −$0.43 | −$0.37 | −$0.34 | −$0.37 | −$1.52 | −$0.93 | −$4.45 | −$7.66 |
| Gross margin | — | 100.0% | — | — | — | — | — | — |
| Operating margin | — | −6,661.8% | — | — | — | — | — | — |
| Net margin | — | −5,808.8% | — | — | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $850,000 | $0 | $2.8M | $0 |
| Cost of revenue | — | $368,000 | $370,000 | — | $367,000 | — | — | — | $0 | $463,000 | $468,000 | $466,000 |
| Gross profit | — | −$368,000 | −$370,000 | — | −$367,000 | — | — | — | $850,000 | −$463,000 | $2.4M | −$466,000 |
| Research & development | $19.6M | $13.4M | $13.7M | $12.8M | $16.4M | $13.1M | $13.0M | $8.6M | $11.2M | $9.5M | $12.4M | $8.8M |
| Sales, general & admin | $7.4M | $6.9M | $4.3M | $3.0M | $4.7M | $4.9M | $3.5M | $3.6M | $4.7M | $3.2M | $3.3M | $3.1M |
| Total operating expenses | $27.0M | $19.9M | $17.6M | $15.8M | $21.1M | $18.0M | $16.6M | $12.2M | $15.9M | $12.8M | $15.4M | $11.9M |
| Operating income | −$27.0M | −$20.3M | −$18.0M | −$15.8M | −$21.1M | −$18.0M | −$16.6M | −$12.2M | −$15.0M | −$12.8M | −$15.4M | −$11.9M |
| Interest income | $1.8M | — | $2.3M | $1.6M | $1.2M | — | $1.6M | $1.8M | $2.0M | — | $2.0M | $2.0M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $1.9M | — |
| Income before taxes | −$25.2M | −$18.3M | −$15.7M | −$14.3M | −$19.9M | −$16.6M | −$15.0M | −$10.5M | −$13.1M | −$10.8M | −$13.4M | −$10.0M |
| Income taxes | — | — | — | — | — | — | — | — | — | $419,724 | $1.9M | $505,586 |
| Net income | −$25.2M | −$18.3M | −$15.7M | −$14.3M | −$19.9M | −$16.6M | −$15.0M | −$10.5M | −$13.1M | −$10.8M | −$13.4M | −$10.0M |
| EBITDA | −$24.8M | −$17.9M | −$15.3M | −$13.9M | −$19.5M | −$16.3M | −$14.7M | −$10.0M | −$12.6M | −$10.3M | −$13.3M | −$9.5M |
| EPS (diluted) | −$0.13 | −$0.10 | −$0.09 | −$0.08 | −$0.14 | −$0.12 | −$0.11 | −$0.08 | −$0.10 | −$0.08 | −$0.11 | −$0.08 |
| Gross margin | — | — | — | — | — | — | — | — | 100.0% | — | 83.5% | — |
| Operating margin | — | — | — | — | — | — | — | — | −1,770.0% | — | −541.2% | — |
| Net margin | — | — | — | — | — | — | — | — | −1,538.4% | — | −471.7% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CMPX's financial statements (latest annual report filed March 5, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CMPX financial results
Compass Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $66.5 million. Diluted earnings per share came to −$0.43.
See the CMPX stock overview for the latest quote and news, or the CMPX chart for price history and technical indicators.
CMPX income statement FAQ
Does Compass Therapeutics have revenue?
Compass Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Compass Therapeutics profitable?
No. Compass Therapeutics reported a net loss of $66.5 million in fiscal 2025.
How much does Compass Therapeutics spend on research and development?
Compass Therapeutics spent $56.0 million on research and development in fiscal 2025.
What are Compass Therapeutics's earnings per share?
Compass Therapeutics earned $-0.43 per diluted share in fiscal 2025, compared with $-0.37 a year earlier.
When will Compass Therapeutics report its next earnings?
Compass Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026.
When does Compass Therapeutics's fiscal year end?
Compass Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 5, 2026.